行业组件数据 · 2026

溶剂化/水合物

Solvate/Hydrate is a crystalline solid component in pharmaceutical manufacturing where solvent molecules are incorporated into the crystal lattice structure of an Active Pharmaceutical Ingredient (API).

技术定义与适配语境
典型 溶剂化/水合物 会按材料、尺寸公差、适配关系和失效风险在 化学制造 中评估。

A solvate/hydrate is a solid-state form of an Active Pharmaceutical Ingredient where solvent molecules (commonly water for hydrates, or organic solvents like ethanol or methanol for solvates) are stoichiometrically or non-stoichiometrically bound within the crystal lattice. This component is critical in pharmaceutical-grade API production as it affects solubility, stability, bioavailability, and processing characteristics. The formation occurs during crystallization processes where API molecules co-crystallize with solvent molecules, creating distinct crystalline phases with unique physicochemical properties.

组件规格

定义
A solvate/hydrate is a solid-state form of an Active Pharmaceutical Ingredient where solvent molecules (commonly water for hydrates, or organic solvents like ethanol or methanol for solvates) are stoichiometrically or non-stoichiometrically bound within the crystal lattice. This component is critical in pharmaceutical-grade API production as it affects solubility, stability, bioavailability, and processing characteristics. The formation occurs during crystallization processes where API molecules co-crystallize with solvent molecules, creating distinct crystalline phases with unique physicochemical properties.
工作原理
The working principle involves controlled crystallization where API molecules form crystalline structures that incorporate solvent molecules into their lattice through hydrogen bonding, van der Waals forces, or coordination bonds. During pharmaceutical manufacturing, specific temperature, pressure, and solvent conditions are maintained to produce the desired solvate/hydrate form with consistent polymorphic characteristics. The component's functionality depends on maintaining the crystalline integrity during processing, storage, and formulation.
材料
Pharmaceutical-grade crystalline solids composed of API molecules (typically organic compounds with molecular weights 200-1000 Da) and incorporated solvent molecules (water for hydrates: H₂Oorganic solvents like ethanol C₂H₅OHmethanol CH₃OHacetone C₃H₆Oor dichloromethane CH₂Cl₂ for solvates). Purity requirements: ≥99.5% chemical purity≤0.1% residual solvents (per ICH Q3C)particle size distribution: D90 < 200μm.
Flowability
Carr Index: 15-25%
Bulk Density
0.3-0.6 g/cm³
Melting Point
150-300°C (decomposition may occur)
Crystal System
Monoclinic, Triclinic, or Orthorhombic
Hygroscopicity
Low to Moderate (for hydrates)
Compressibility
2-10%
Solvent Content
0.5-20% w/w
Specific Surface Area
0.5-5 m²/g
Particle Size Distribution
D10: 10-50μm, D50: 50-150μm, D90: 150-250μm
标准
ISO 9001ISO 13485ICH Q6AICH Q3CUSP <1151>EP 5.9GMP Guidelines

行业分类与别名

溶剂化/水合物 的常用贸易名称、技术标识和检索关键词。

上级产品

该组件会出现在以下整机或工业产品中。

FMEA · 风险与缓解

诱因 → 失效模式 → 工程缓解

Inadequate humidity control during storage->Hydrate dehydration to anhydrous form->Implement controlled humidity storage (30-60% RH), use desiccant-containing packaging, monitor with humidity sensors
Improper crystallization conditions->Formation of undesired polymorphic forms->Precise temperature control (±0.5°C), controlled cooling rates, in-process monitoring with PAT tools
Solvent contamination from previous batches->Cross-contamination leading to mixed solvate forms->Implement dedicated equipment, rigorous cleaning validation, solvent purity verification

工业生态与工程逻辑

0
Polymorphic transformation during processing
1
Solvent loss leading to form change
2
Hygroscopicity causing stability issues
3
Batch-to-batch variability in crystal form
4
Residual solvent contamination
5
Reduced bioavailability if incorrect form

合规与检测

tolerance
Crystal form purity ≥98%, Solvent content ±2% of target, Particle size D90 ±15%, Residual solvents ≤ICH Class 2 limits
test method
X-ray diffraction for crystal form identification, Karl Fischer titration for water content, GC for residual solvents, Laser diffraction for particle size, DSC for thermal properties

制造该组件的工厂

来自 CNFX 组件能力表的相关制造商资料。

制造商列表用于前期研究和供应商能力理解,不代表认证、排名或交易担保。

采购评估维度

不是客户评论,也不是实时热度。以下维度用于前期 RFQ 准备和供应商评估。

技术文档
4/5
制造能力
4/5
可检验性
5/5
供应商透明度
3/5

这些分值是采购评估维度示例,不代表真实客户评分、具体国家买家反馈或实时询盘。

相关组件

常见问题

What is the difference between a solvate and a hydrate?

A hydrate specifically contains water molecules in its crystal lattice, while a solvate contains other solvent molecules (ethanol, methanol, acetone, etc.). Hydrates are a subset of solvates where the solvent is water.

Why are solvate/hydrate forms important in pharmaceutical manufacturing?

They significantly impact drug product performance including solubility, dissolution rate, stability, bioavailability, and manufacturability. Different solvate/hydrate forms can have dramatically different therapeutic properties and shelf life.

How are solvate/hydrate forms characterized and controlled?

Through techniques like X-ray diffraction (XRD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), infrared spectroscopy (IR), and solid-state NMR. Manufacturing controls include strict temperature, humidity, and solvent composition monitoring during crystallization.

我可以直接联系工厂吗?

CNFX 是开放目录,不是交易平台或采购代理。工厂资料和表单用于帮助你准备直接沟通。

CNFX Industrial Component Index · 化学制造

数据基础

CNFX 制造商资料、技术分类、公开产品信息和持续合理性检查。

初步技术归类
本页用于结构化准备研究、RFQ 和供应商评估,不替代买方自己的供应商资质审查、标准核验和技术批准。

请求制造能力信息: 溶剂化/水合物

说明目标数量、应用场景、交期和关键技术要求,用于准备 RFQ 或供应商评估。

谢谢,信息已发送。
谢谢,信息已收到。

需要制造 溶剂化/水合物?

对比具备该组件加工或装配能力的制造商资料。

创建制造商档案 联系我们
上一个组件
添加剂(如流动助剂)
下一个组件
滴管/孔板
URN:CNFX:ME:UNIT:SOLVATE_HYDRATE